Press Release: electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

Dow Jones

2024/11/09

electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

ROCKAWAY, N.J., Nov. 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the "Company"), $(ECOR)$, a commercial-stage bioelectronic medicine and wellness company, today announced that Thomas Freeburg will join electroCore, effective November 11, 2024, as the Company's VP, Corporate Controller. The Compensation Committee of electroCore's Board of Directors granted 5,000 restricted stock units ("RSUs") to Mr. Freeburg in connection with the commencement of his employment. The RSUs were granted as an inducement material to Mr. Freeburg's commencement of employment pursuant to NASDAQ Listing Rule 5635(c)(4). 33% of the RSUs will vest on each of the first, second and third anniversaries of the date of grant, subject to Mr. Freeburg's continued employment by the Company on the applicable vesting date. Upon vesting, the RSUs shall be settled in shares of the Company's common stock.

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health and promoting general wellness through its non-invasive vagus nerve stimulation ("nVNS") technology platform. The company's is focused on the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.

For more information, visit www.electrocore.com.

Contact:

ECOR Investor Relations

(973) 302-9253

investors@electrocore.com

(END) Dow Jones Newswires

November 08, 2024 16:01 ET (21:01 GMT)

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2482532904"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2482532904\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2482532904?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-09 05:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2482532904","market":"nz","top_or_hot":-1,"title":"Press Release: electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) \n</p>\n<p>\n     ROCKAWAY, N.J., Nov. 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the \"Company\"), <a href=\"https://laohu8.com/S/ECOR\">$(ECOR)$</a>, a commercial-stage bioelectronic medicine and wellness company, today announced that Thomas Freeburg will join electroCore, effective November 11, 2024, as the Company's <a href=\"https://laohu8.com/S/VP..UK\">VP</a>, Corporate Controller. The Compensation Committee of electroCore's Board of Directors granted 5,000 restricted stock units (\"RSUs\") to Mr. Freeburg in connection with the commencement of his employment. The RSUs were granted as an inducement material to Mr. Freeburg's commencement of employment pursuant to NASDAQ Listing Rule 5635(c)(4). 33% of the RSUs will vest on each of the first, second and third anniversaries of the date of grant, subject to Mr. Freeburg's continued employment by the Company on the applicable vesting date. Upon vesting, the RSUs shall be settled in shares of the Company's common stock. \n</p>\n<p>\n     About electroCore, Inc. \n</p>\n<p>\n     electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health and promoting general wellness through its non-invasive vagus nerve stimulation (\"nVNS\") technology platform. The company's is focused on the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets. \n</p>\n<p>\n     For more information, visit www.electrocore.com. \n</p>\n<p>\n     Contact: \n</p>\n<p>\n     ECOR Investor Relations \n</p>\n<p>\n     (973) 302-9253 \n</p>\n<p>\n     investors@electrocore.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 08, 2024 16:01 ET (21:01 GMT)\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Press Release: electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPress Release: electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-11-09 05:01</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) \n</p>\n<p>\n     ROCKAWAY, N.J., Nov. 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the \"Company\"), <a href=\"https://laohu8.com/S/ECOR\">$(ECOR)$</a>, a commercial-stage bioelectronic medicine and wellness company, today announced that Thomas Freeburg will join electroCore, effective November 11, 2024, as the Company's <a href=\"https://laohu8.com/S/VP..UK\">VP</a>, Corporate Controller. The Compensation Committee of electroCore's Board of Directors granted 5,000 restricted stock units (\"RSUs\") to Mr. Freeburg in connection with the commencement of his employment. The RSUs were granted as an inducement material to Mr. Freeburg's commencement of employment pursuant to NASDAQ Listing Rule 5635(c)(4). 33% of the RSUs will vest on each of the first, second and third anniversaries of the date of grant, subject to Mr. Freeburg's continued employment by the Company on the applicable vesting date. Upon vesting, the RSUs shall be settled in shares of the Company's common stock. \n</p>\n<p>\n     About electroCore, Inc. \n</p>\n<p>\n     electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health and promoting general wellness through its non-invasive vagus nerve stimulation (\"nVNS\") technology platform. The company's is focused on the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets. \n</p>\n<p>\n     For more information, visit www.electrocore.com. \n</p>\n<p>\n     Contact: \n</p>\n<p>\n     ECOR Investor Relations \n</p>\n<p>\n     (973) 302-9253 \n</p>\n<p>\n     investors@electrocore.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 08, 2024 16:01 ET (21:01 GMT)\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210150020.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2482532904","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482532904","pubTimestamp":1731099660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"ROCKAWAY, N.J., Nov. 08, 2024  -- electroCore, Inc. , , a commercial-stage bioelectronic medicine and wellness company, today announced that Thomas Freeburg will join electroCore, effective November 11, 2024, as the Company's VP, Corporate Controller. The Compensation Committee of electroCore's Board of Directors granted 5,000 restricted stock units  to Mr. Freeburg in connection with the commencement of his employment. The RSUs were granted as an inducement material to Mr. Freeburg's commencement of employment pursuant to NASDAQ Listing Rule 5635. 33% of the RSUs will vest on each of the first, second and third anniversaries of the date of grant, subject to Mr. Freeburg's continued employment by the Company on the applicable vesting date. Upon vesting, the RSUs shall be settled in shares of the Company's common stock.electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health and promoting general wellness through its non-invasive ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","TQQQ":"纳指三倍做多ETF","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","SQQQ":"纳指三倍做空ETF","BK4082":"医疗保健设备","ECOR":"Electrocore LLC","QID":"两倍做空纳斯达克指数ETF-ProShares","BK4588":"碎股","BK4112":"金融交易所和数据","PSQ":"做空纳斯达克100指数ETF-ProShares","NDAQ":"纳斯达克OMX交易所","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC",".IXIC":"NASDAQ Composite","BK4585":"ETF&股票定投概念","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","QLD":"2倍做多纳斯达克100指数ETF-ProShares"},"translate_title":"新闻稿：electroCore宣布根据纳斯达克上市规则5635(c)(4)授予奖励","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QLD":0.6,"MNQmain":0.6,"SQQQ":0.6,"NQmain":1,"TQQQ":0.6,"PSQ":0.6,"NDAQ":1,".IXIC":1,"ECOR":0.9,"QID":0.6},"content_text":"electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) \n\n\n     ROCKAWAY, N.J., Nov. 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the \"Company\"), $(ECOR)$, a commercial-stage bioelectronic medicine and wellness company, today announced that Thomas Freeburg will join electroCore, effective November 11, 2024, as the Company's VP, Corporate Controller. The Compensation Committee of electroCore's Board of Directors granted 5,000 restricted stock units (\"RSUs\") to Mr. Freeburg in connection with the commencement of his employment. The RSUs were granted as an inducement material to Mr. Freeburg's commencement of employment pursuant to NASDAQ Listing Rule 5635(c)(4). 33% of the RSUs will vest on each of the first, second and third anniversaries of the date of grant, subject to Mr. Freeburg's continued employment by the Company on the applicable vesting date. Upon vesting, the RSUs shall be settled in shares of the Company's common stock. \n\n\n     About electroCore, Inc. \n\n\n     electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health and promoting general wellness through its non-invasive vagus nerve stimulation (\"nVNS\") technology platform. The company's is focused on the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets. \n\n\n     For more information, visit www.electrocore.com. \n\n\n     Contact: \n\n\n     ECOR Investor Relations \n\n\n     (973) 302-9253 \n\n\n     investors@electrocore.com \n\n\n  (END) Dow Jones Newswires\n\n\n  November 08, 2024 16:01 ET (21:01 GMT)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}